Stock Activity Watchlist: Rand Capital (NASDAQ:RAND), Synthesis Energy Systems (NASDAQ:SYMX), Meridian Bioscience (NASDAQ:VIVO), Kulicke and Soffa Industries (NASDAQ:KLIC), ACADIA Pharmaceuticals (NASDAQ:ACAD)

On 09 September, Rand Capital Corporation (NASDAQ:RAND) shares increased 0.53% and was closed at $3.82. RAND EPS growth in last 5 year was 51.30%. Rand Capital Corporation (NASDAQ:RAND) year to date (YTD) performance is -6.60%.

Rand Capital (NASDAQ:RAND) provides investors the ability to participate in venture capital opportunities through an investment in the Company’s stock. Rand is a Business Development Company (BDC), and its wholly-owned subsidiary is licensed by the U.S. Small Business Administration (SBA) as a Small Business Investment Company (SBIC).

Rand Capital Corporation (NASDAQ:RAND), announced that it recently invested $250,000 as part of a $4.3 million equity capital funding round in SciAps, Inc. (http://sciaps.com/). SciAps is the leading provider of handheld analytical instruments used in industrial, service/security, and mining markets to identify and analyze compounds, minerals and elements. The funding round was led by new investor Jolimont Global Mining Systems (“Jolimont Global”) (http://jolimontgms.com/) with participation from Rand Capital, and other existing investors including SciAps CEO and Founder Donald Sackett, as well as two additional new investors.

Synthesis Energy Systems, Inc. (NASDAQ:SYMX) shares moved down -4.04% in last trading session and ended the day at $0.95. SYMX Gross Margin is -33.60% and its has a return on assets of -50.40%. Synthesis Energy Systems, Inc. (NASDAQ:SYMX) quarterly performance is -37.09%.

Synthesis Energy Systems (SES) is a Houston-based technology company focused on bringing clean high-value energy to developing countries from low-cost and low-grade coal and biomass through its proprietary gasification technology based upon U-Gas®, licensed from the Gas Technology Institute.

Synthesis Energy Systems, Inc. (NASDAQ:SYMX), reports a progress update from its Tianwo-SES Clean Energy Technologies Company Joint Venture in China. The second of three previously announced natural gas replacement projects under construction for Aluminum Corporation of China Limited (CHALCO) (hkex:2600) , located in Xing County, Shanxi Province, has completed installation of the facility’s single SES Gasification Technology system.

Meridian Bioscience, Inc. (NASDAQ:VIVO) Wednesday said it expects fiscal 2016 earnings in a range of $0.86 to $0.90 per share. On average, 7 analysts polled by Thomson Reuters were looking for $0.86 per share. Net revenue is projected to increase 3 to 5 percent to a range of $195 to $200 million. Wall Street projects $196.37 million. The company’s earlier projection was earnings of $0.85 per share and revenue of $193 million. Foreign currency translations had a negative impact of $3 million on net revenue.
Meridian Bioscience, Inc. (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.
Meridian Bioscience, Inc. (NASDAQ:VIVO) caters to the Healthcare space. It has a net profit margin of 18.10% and weekly performance is -3.82%. On the last day of trading company shares ended up $17.62. Meridian Bioscience, Inc. (NASDAQ:VIVO) distance from 50-day simple moving average (SMA50) is -4.54%.

On 09 September, Kulicke and Soffa Industries, Inc. (NASDAQ:KLIC) shares decreased -7.02% and was closed at $9.94. KLIC EPS growth in last 5 year was 22.80%. Kulicke and Soffa Industries, Inc. (NASDAQ:KLIC) year to date (YTD) performance is -31.26%.

Kulicke & Soffa (NASDAQ: KLIC) is a global leader in the design and manufacture of semiconductor, LED and electronic assembly equipment. As a pioneer in this industry, K&S has provided customers with market leading packaging solutions for decades.

Kulicke and Soffa Industries, Inc. (NASDAQ:KLIC) announced its fourth fiscal quarter revenue is expected to be below the company’s previously reported outlook due to broad-based industry softness. The Company now expects fourth quarter revenue to be in the $100 to $110 million range, compared to the previously expected $135 to $145 million range.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) caters to the Healthcare space. Its weekly performance is 12.03%. On the last day of trading company shares ended up $40.23. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) distance from 50-day simple moving average (SMA50) is -5.39%.

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for which we have submitted a New Drug Application in Parkinson’s disease psychosis to the FDA and which has the potential to be the first drug approved in the United States for this condition.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), announced that its Board of Directors has appointed Steve Davis as President and Chief Executive Officer. Mr. Davis has been serving as ACADIA’s Interim Chief Executive Officer since March 2015. Mr. Davis has also been appointed to the ACADIA Board of Directors.